Sumitomo Corp Reports 11% Drop in Net Profit Amid Weak Coal Prices 
BOJ Maintains Low Interest Rates Amid Economic Scrutiny 
Visa Tops Profit Expectations as Consumer Spending Defies Economic Concerns and Drives Growth 
XRP's Decentralized ID Revolutionizes Digital Security: Self-Sovereign IDs Go Live on XRPL 
Cybertruck to Hit Canada Next Week: Tesla’s First Canadian Deliveries Set for Nov. 5 
Samsung Electronics Refocuses on High-End Chips Amid Profit Dip and AI Demand 
Xiaomi SU7 Ultra Makes EV History at Nürburgring, Leaving Porsche and Tesla in Its Dust 
Major Banks Report Profit Increases Amid NIM Pressures 
1.74B DOGE Moves to Robinhood as Whale Transfers Spark Fear of Dogecoin Sell-Off 
Missouri Mother Seeks $6 Billion in Lawsuit Over Premature Baby Formula Risks 
Xiaomi SU7 Ultra Pre-Sale Begins in China for $114K with 1,500 HP, Hits 100 km/h in 2 Seconds 
Utilizing Blockchain Technology for Transparent and Decentralized Gold Trading 
BlackRock’s $2.2 Billion Bitcoin ETF Stands Out, Surpassing Top Global Funds in Unmatched Inflow 
Shiba Inu's 6 Trillion Token Shift Breaks October Record, Sparks Market Debate on SHIB’s Next Move 
Reddit Dumps Bitcoin and Ethereum Holdings; SEC Filing Shows Crypto Exit in Q3 2024 
Shiba Inu's Shytoshi Unveils Unprecedented 33,774,726% SHIB Surge, Overshadowing Bitcoin and Dogecoin 
Bitcoin Miners Turn to AI and Strategic Mergers as Halving Pressures Profitability: CoinShares Report 
SAN DIEGO, Nov. 09, 2017 -- Kura Oncology, Inc., (Nasdaq:KURA) a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will host an Investor Day on Thursday, November 16, 2017, from 8:30 a.m. to 10:30 a.m. ET in New York City. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, and Antonio Gualberto, M.D., Ph.D., Chief Medical Officer, will provide a comprehensive overview of the company’s clinical development program for its lead product candidate, tipifarnib, in HRAS mutant head and neck squamous cell carcinoma (HNSCC).
Interested parties may access a live audio webcast and slides of the presentations on the investor section of Kura’s website at www.kuraoncology.com beginning at 8:30 a.m. ET. An archive of the webcast will be available shortly after the event and can be viewed at the same link for a limited time.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. Kura’s pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 trial, and KO-539, an inhibitor of the menin-MLL protein-protein interaction, currently in preclinical testing. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.
CONTACTS
Pete De Spain
Vice President, Investor Relations &
Corporate Communications
Kura Oncology, Inc.
(858) 500-8803
[email protected]
Robert H. Uhl
Managing Director
Westwicke Partners, LLC
(858) 356-5932
[email protected]
